CD22 is a suitable target molecule for detection and high-dose, myeloablative radioimmunotherapy with the monoclonal antibody LL2 in acute lymphatic leukaemia and Waldenstrom's macroglobulinaemia

Tumor Targeting

Volumn 3, Issue 1, 1998, Pages 32-40

  Behr, T M ^a   Holler, E ^a   Gratz, S ^a   Wormann, B ^a   Sharkey, R M ^a   Dunn, R M ^a   Hiddemann, W ^a   Kolb, H J ^a   Goldenberg, D M ^a   Becker, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Acute lymphatic leukaemia; CD22; High dose myeloablative therapy; Lymphoma; Radioimmunotherapy; Waldenstrom's macroglobulinaemia

Indexed keywords

ANTIMONY TRISULFIDE TC 99M COLLOID; CD22 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 22; MONOCLONAL ANTIBODY LL 2; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CASE REPORT; DRUG LABELING; DRUG TARGETING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REMISSION; TARGET CELL DESTRUCTION; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0031778541     PISSN: 13518488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)